Alector, Inc. (ALEC)
USD 0.95
(-7.11%)
USD 0.95
(-7.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 248.8 Million USD | -8.34% |
| 2022 | 271.45 Million USD | 11.05% |
| 2021 | 244.44 Million USD | 13.03% |
| 2020 | 216.27 Million USD | 59.47% |
| 2019 | 135.62 Million USD | 59.62% |
| 2018 | 84.96 Million USD | 133.33% |
| 2017 | 36.41 Million USD | 134.2% |
| 2016 | 15.54 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 58.4 Million USD | -2.0% |
| 2024 Q1 | 59.6 Million USD | -4.86% |
| 2023 Q4 | 62.64 Million USD | 4.94% |
| 2023 Q2 | 59.8 Million USD | -10.29% |
| 2023 FY | 248.8 Million USD | -8.34% |
| 2023 Q1 | 66.66 Million USD | -4.6% |
| 2023 Q3 | 59.69 Million USD | -0.19% |
| 2022 Q1 | 68.59 Million USD | -1.61% |
| 2022 Q3 | 62.6 Million USD | -11.05% |
| 2022 FY | 271.45 Million USD | 11.05% |
| 2022 Q2 | 70.37 Million USD | 2.59% |
| 2022 Q4 | 69.87 Million USD | 11.63% |
| 2021 Q3 | 56.08 Million USD | -9.39% |
| 2021 FY | 244.44 Million USD | 13.03% |
| 2021 Q2 | 61.89 Million USD | 9.07% |
| 2021 Q4 | 69.72 Million USD | 24.32% |
| 2021 Q1 | 56.74 Million USD | -1.5% |
| 2020 Q2 | 49.75 Million USD | 1.04% |
| 2020 Q3 | 59.65 Million USD | 19.88% |
| 2020 Q4 | 57.61 Million USD | -3.42% |
| 2020 FY | 216.27 Million USD | 59.47% |
| 2020 Q1 | 49.24 Million USD | 28.44% |
| 2019 Q3 | 36.84 Million USD | 8.15% |
| 2019 FY | 135.62 Million USD | 59.62% |
| 2019 Q2 | 34.06 Million USD | 29.22% |
| 2019 Q1 | 26.36 Million USD | -6.38% |
| 2019 Q4 | 38.34 Million USD | 4.07% |
| 2018 Q2 | 19.34 Million USD | 36.73% |
| 2018 Q3 | 23.31 Million USD | 20.57% |
| 2018 FY | 84.96 Million USD | 133.33% |
| 2018 Q1 | 14.14 Million USD | 9.94% |
| 2018 Q4 | 28.16 Million USD | 20.77% |
| 2017 Q3 | 2.2 Million USD | 109.61% |
| 2017 Q1 | 1.05 Million USD | 0.0% |
| 2017 Q2 | 1.05 Million USD | 0.0% |
| 2017 Q4 | 12.86 Million USD | 484.02% |
| 2017 FY | 36.41 Million USD | 134.2% |
| 2016 FY | 15.54 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 9.603% |
| Alkermes plc | 996.24 Million USD | 75.026% |
| Agenus Inc. | 78.18 Million USD | -218.23% |
| Aptorum Group Limited | 10.56 Thousand USD | -2354641.624% |
| Ardelyx, Inc. | 169.93 Million USD | -46.408% |
| Dyadic International, Inc. | 9.15 Million USD | -2618.347% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1018.06% |
| Lantern Pharma Inc. | 17.87 Million USD | -1291.699% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3595.842% |
| Novavax, Inc. | 779.12 Million USD | 68.066% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -206.928% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -202.694% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1181.262% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -740.377% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -368.321% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 34.611% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -923.598% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -557.007% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -708.56% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -193.69% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1325.228% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -47.713% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -660.514% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -55.709% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 86.178% |
| AlloVir, Inc. | 180.93 Million USD | -37.511% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 44.182% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -738.225% |
| Bicycle Therapeutics plc | 216.92 Million USD | -14.697% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -44.735% |
| ChromaDex Corporation | 56.37 Million USD | -341.303% |
| Chimerix, Inc. | 93.38 Million USD | -166.415% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1688.702% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -65.277% |
| CRISPR Therapeutics AG | 463.49 Million USD | 46.32% |
| Precision BioSciences, Inc. | 92.46 Million USD | -169.083% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 2.063% |
| Fortress Biotech, Inc. | 200.19 Million USD | -24.28% |
| Fortress Biotech, Inc. | 200.19 Million USD | -24.28% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -659.794% |
| ImmuCell Corporation | 9.61 Million USD | -2487.009% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -57.655% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1441.418% |
| Incyte Corporation | 1.19 Billion USD | 79.101% |
| Innoviva, Inc. | 132.15 Million USD | -88.267% |
| IO Biotech, Inc. | 91.44 Million USD | -172.084% |
| Jaguar Health, Inc. | 42.01 Million USD | -492.174% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -46.979% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -195.058% |
| ContextLogic Inc. | 387 Million USD | 35.71% |
| MiMedx Group, Inc. | 229.72 Million USD | -8.303% |
| MEI Pharma, Inc. | 34.78 Million USD | -615.257% |
| NextCure, Inc. | 67.63 Million USD | -267.849% |
| Onconetix, Inc. | 34.9 Million USD | -612.748% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1852.001% |
| Opthea Limited | 191.96 Million USD | -29.606% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -8942.134% |
| Vaxcyte, Inc. | 468.04 Million USD | 46.842% |
| PDS Biotechnology Corporation | 43.04 Million USD | -478.001% |
| Precigen, Inc. | 84.18 Million USD | -195.556% |
| Pharming Group N.V. | 225.49 Million USD | -10.338% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -48.249% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -242.863% |
| PureTech Health plc | 144.59 Million USD | -72.066% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -91.0% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -1.486% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -923.598% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -8.799% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -706.254% |
| Acelyrin, Inc. | 422.06 Million USD | 41.051% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1929495.161% |
| Summit Therapeutics Inc. | 87.68 Million USD | -183.742% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -571.277% |
| Senti Biosciences, Inc. | 94.7 Million USD | -162.713% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -101.373% |
| Elevation Oncology, Inc. | 45.44 Million USD | -447.479% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -744.284% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -6211.491% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -88.237% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -629.946% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2844.054% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -37.231% |
| Seer, Inc. | 110.49 Million USD | -125.181% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -252.441% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -166.161% |
| ESSA Pharma Inc. | 32.13 Million USD | -674.262% |
| GlycoMimetics, Inc. | 39.28 Million USD | -533.321% |
| GT Biopharma, Inc. | 13.57 Million USD | -1732.661% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -13.179% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -23.711% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 4.095% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -338.348% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -360.063% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2403.631% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 38.349% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1214.396% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -390.801% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 4.181% |
| Aptose Biosciences Inc. | 52.35 Million USD | -375.212% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1626.548% |
| Soligenix, Inc. | 7.79 Million USD | -3091.712% |
| Century Therapeutics, Inc. | 56.07 Million USD | -343.727% |
| Kura Oncology, Inc. | 165.8 Million USD | -50.058% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -117.281% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2890.768% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -9925.713% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -131.018% |
| Autolus Therapeutics plc | 196.72 Million USD | -26.471% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -193.894% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -113.65% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1183.609% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 22.674% |
| GRI Bio, Inc. | 11.33 Million USD | -2095.958% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3426.255% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -89.646% |
| IGM Biosciences, Inc. | 265.59 Million USD | 6.321% |
| INmune Bio, Inc. | 29.89 Million USD | -732.225% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -44.188% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -517.156% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1457.021% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1480.543% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -300.66% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -131.396% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 9.754% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 17.465% |
| Verastem, Inc. | 92.08 Million USD | -170.19% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1286.933% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -33.963% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -104.932% |
| Histogen Inc. | 14.27 Million USD | -1643.288% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1450.348% |
| Surrozen, Inc. | 18.55 Million USD | -1241.251% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1568.133% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4787.828% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -316.941% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -870.102% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -429.298% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -3159.624% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -39.67% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -413.545% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -1.55% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1519.112% |
| Apollomics, Inc. | 54.14 Million USD | -359.553% |
| Amarin Corporation plc | 272.35 Million USD | 8.649% |
| Mesoblast Limited | 5.9 Million USD | -4115.554% |
| Turnstone Biologics Corp. | 78.33 Million USD | -217.601% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -1.917% |
| Synaptogenix, Inc. | 8.31 Million USD | -2892.619% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1605.759% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 1.681% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -646.479% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2717.296% |
| Exelixis, Inc. | 1.58 Billion USD | 84.32% |
| Better Therapeutics, Inc. | 38.26 Million USD | -550.259% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -7.219% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 70.907% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2007.23% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2993.819% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -729.534% |
| Gritstone bio, Inc. | 148.37 Million USD | -67.686% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -261.31% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1420.774% |
| Avid Bioservices, Inc. | 25.99 Million USD | -857.078% |
| Insmed Incorporated | 949.26 Million USD | 73.79% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1485.758% |
| MediWound Ltd. | 18.86 Million USD | -1218.645% |
| OmniAb, Inc. | 83.89 Million USD | -196.564% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -6.186% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -376.167% |
| Zai Lab Limited | 547.47 Million USD | 54.555% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 37.589% |
| Aura Biosciences, Inc. | 84.99 Million USD | -192.739% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -0.673% |
| Immunic, Inc. | 99.22 Million USD | -150.75% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -56.467% |
| Veracyte, Inc. | 357.93 Million USD | 30.489% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.24% |
| FibroGen, Inc. | 398.11 Million USD | 37.505% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1650.894% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3512.136% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3391.599% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 92.358% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -861.628% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 21.4% |
| TG Therapeutics, Inc. | 198.47 Million USD | -25.357% |
| Galecto, Inc. | 35.62 Million USD | -598.352% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -511.472% |
| Fortrea Holdings Inc. | 457.3 Million USD | 45.593% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -358.385% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -761.562% |
| XBiotech Inc. | 37.51 Million USD | -563.295% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -261.31% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1104.911% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -75.137% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -151.125% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -124.721% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 74.036% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -762.548% |
| Vaxxinity, Inc. | 56.05 Million USD | -343.885% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 42.225% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1015.288% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -124.415% |
| NexImmune, Inc. | 28.16 Million USD | -783.294% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4398.361% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1290.537% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.163% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -877.265% |
| Scopus BioPharma Inc. | 11.71 Million USD | -2023.812% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -95.811% |
| Ainos, Inc. | 12.95 Million USD | -1820.856% |
| Pluri Inc. | 22.48 Million USD | -1006.77% |
| Prothena Corporation plc | 282.4 Million USD | 11.899% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -24.387% |
| Celularity Inc. | 215.05 Million USD | -15.691% |
| Rallybio Corporation | 78.93 Million USD | -215.211% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1173.165% |
| MeiraGTx Holdings plc | 151.07 Million USD | -64.684% |
| Omeros Corporation | 94.75 Million USD | -162.585% |
| Humacyte, Inc. | 23.49 Million USD | -958.867% |
| Immunocore Holdings plc | 308.04 Million USD | 19.231% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -7239.292% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -186.424% |
| Blueprint Medicines Corporation | 722.86 Million USD | 65.581% |
| CalciMedica, Inc. | 21.81 Million USD | -1040.404% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -233.247% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -54.978% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -45.248% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 15.643% |
| Pulmatrix, Inc. | 22.03 Million USD | -1028.968% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -619.601% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -179.974% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 54.892% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -242.934% |
| Cytokinetics, Incorporated | 173.61 Million USD | -43.309% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -622.862% |
| Nutriband Inc. | 5.73 Million USD | -4239.042% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -470.477% |
| Vor Biopharma Inc. | 126.03 Million USD | -97.406% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 79.078% |
| Evogene Ltd. | 27.79 Million USD | -795.293% |
| ProKidney Corp. | 151.52 Million USD | -64.202% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -235.426% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -3134.454% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 59.493% |
| CorMedix Inc. | 48.95 Million USD | -408.197% |
| BioLineRx Ltd. | 50.8 Million USD | -389.748% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -65.098% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -553.504% |
| Atai Life Sciences N.V. | 125.78 Million USD | -97.799% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -204.758% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -205.62% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 1.485% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -659.933% |
| MediciNova, Inc. | 10.9 Million USD | -2182.532% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -93.139% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3327.25% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4031.432% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 47.77% |
| Biomea Fusion, Inc. | 126.13 Million USD | -97.251% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 81.034% |
| Mereo BioPharma Group plc | 35.84 Million USD | -594.163% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -30.202% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -8.196% |
| Absci Corporation | 73.66 Million USD | -237.743% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -802.045% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -86.243% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -2.742% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 5.055% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -19.62% |
| Allakos Inc. | 196.05 Million USD | -26.904% |
| Imunon, Inc. | 20.31 Million USD | -1124.997% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -119.269% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 32.503% |
| BioAtla, Inc. | 129.68 Million USD | -91.848% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2007.23% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1470.422% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -192.991% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -495.819% |
| XOMA Corporation | 46.46 Million USD | -435.484% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -123.801% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -74.643% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1816.958% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -140.027% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -43.924% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 2.34% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -565.104% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2925.017% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1380.436% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10841.305% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 16.877% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3597.607% |
| UroGen Pharma Ltd. | 138.88 Million USD | -79.139% |
| Sutro Biopharma, Inc. | 243 Million USD | -2.384% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -3320.136% |
| Orgenesis Inc. | 45.75 Million USD | -443.746% |
| Entera Bio Ltd. | 8.86 Million USD | -2708.149% |
| GH Research PLC | 41.22 Million USD | -503.566% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -867.8% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -199.57% |
| Xencor, Inc. | 306.97 Million USD | 18.951% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4943.005% |
| Replimune Group, Inc. | 234.77 Million USD | -5.976% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1114.267% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -29.722% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3597.607% |
| Portage Biotech Inc. | 18.19 Million USD | -1267.119% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3327.25% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -137.042% |
| OncoCyte Corporation | 25.63 Million USD | -870.48% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3981.661% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2071.604% |
| Purple Biotech Ltd. | -22.46 Million USD | 1207.411% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1409.721% |
| scPharmaceuticals Inc. | 65.17 Million USD | -281.727% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2843.449% |
| HilleVax, Inc. | 133.34 Million USD | -86.585% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2319.076% |
| Tharimmune, Inc. | 9.45 Million USD | -2531.372% |
| Genprex, Inc. | 31.06 Million USD | -701.022% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -32.676% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -692.944% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -32423.137% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4467.757% |
| OKYO Pharma Limited | 8243.57 USD | -3018034.134% |
| Savara Inc. | 15.74 Million USD | -1480.197% |
| Curis, Inc. | 58.35 Million USD | -326.359% |
| Daré Bioscience, Inc. | 33.6 Million USD | -640.275% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4785.667% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -3234.7% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -820.739% |
| BeiGene, Ltd. | 3.28 Billion USD | 92.43% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1147.797% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 50.116% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -61.926% |
| Erasca, Inc. | 141.52 Million USD | -75.801% |
| bluebird bio, Inc. | 240.23 Million USD | -3.567% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5395.989% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 85.752% |
| DBV Technologies S.A. | 92.16 Million USD | -169.967% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5395.989% |
| Moderna, Inc. | 6.39 Billion USD | 96.109% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -483.919% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1631.881% |
| Molecular Templates, Inc. | 63.09 Million USD | -294.354% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -273.011% |
| Travere Therapeutics, Inc. | 472 Million USD | 47.288% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -73.61% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -300.764% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -473.092% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -19.542% |
| MacroGenics, Inc. | 217.21 Million USD | -14.542% |
| RenovoRx, Inc. | 11.39 Million USD | -2083.24% |
| Adicet Bio, Inc. | 152.03 Million USD | -63.645% |
| Prime Medicine, Inc. | 186.63 Million USD | -33.307% |
| Aditxt, Inc. | 25.95 Million USD | -858.746% |
| Adagene Inc. | 41.83 Million USD | -494.774% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3303.539% |
| Quantum-Si incorporated | 111.65 Million USD | -122.823% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -44.779% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1606.722% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -594.551% |
| SciSparc Ltd. | 9.01 Million USD | -2661.092% |
| Vericel Corporation | 142.04 Million USD | -75.163% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2774.109% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -977.597% |
| Generation Bio Co. | 144.46 Million USD | -72.221% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -199.653% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -187.765% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 15.866% |
| Invivyd, Inc. | 205.75 Million USD | -20.921% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -244.797% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2552.896% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -230.616% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2318.606% |
| 2seventy bio, Inc. | 289.88 Million USD | 14.173% |
| ADMA Biologics, Inc. | 66.58 Million USD | -273.655% |
| Clene Inc. | 41.07 Million USD | -505.756% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1842.569% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -354.051% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4031.432% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 29.327% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -577.344% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -637.672% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -139.92% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -663.454% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -46.115% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 67.592% |
| Evaxion Biotech A/S | 22.27 Million USD | -1017.207% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -83.558% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -5.926% |
| Trevena, Inc. | 38.41 Million USD | -547.703% |
| Surrozen, Inc. | 18.55 Million USD | -1241.251% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -211.216% |
| Cingulate Inc. | 22.75 Million USD | -993.194% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3420.902% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -457.015% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2921.664% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -142.596% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 67.006% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -300.815% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2746.265% |
| Kronos Bio, Inc. | 128.11 Million USD | -94.198% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -195.939% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8382.894% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -146.761% |
| Statera Biopharma, Inc. | 28.82 Million USD | -763.012% |
| ImmunityBio, Inc. | 362.87 Million USD | 31.435% |
| Korro Bio, Inc. | 84.53 Million USD | -194.322% |
| Kineta, Inc. | 21.15 Million USD | -1076.035% |
| BioVie Inc. | 31.95 Million USD | -678.718% |
| Codexis, Inc. | 66.51 Million USD | -274.037% |
| Celularity Inc. | 215.05 Million USD | -15.691% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -9.788% |
| Celcuity Inc. | 66.23 Million USD | -275.662% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3700.208% |
| Cibus, Inc. | 320.3 Million USD | 22.323% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -478.609% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -635.144% |
| IN8bio, Inc. | 30.33 Million USD | -720.127% |
| Kodiak Sciences Inc. | 277.32 Million USD | 10.284% |
| Annexon, Inc. | 143.72 Million USD | -73.112% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -95.0% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -986.045% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -38775.313% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 68.085% |
| Eyenovia, Inc. | 25.4 Million USD | -879.287% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -77.317% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4373.247% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -214.41% |
| Arcellx, Inc. | 200.19 Million USD | -24.277% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -442.052% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -14.967% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2398.765% |
| Moolec Science SA | 52.75 Million USD | -371.657% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -306.951% |
| Geron Corporation | 70.44 Million USD | -253.206% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -434.598% |
| Royalty Pharma plc | 862.4 Million USD | 71.15% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -164.48% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2567.298% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -999.506% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -19.725% |
| Humacyte, Inc. | 23.49 Million USD | -958.867% |
| Structure Therapeutics Inc. | 102.77 Million USD | -142.084% |
| 89bio, Inc. | 151.2 Million USD | -64.547% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -210.49% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1611.155% |
| Genelux Corporation | 24.33 Million USD | -922.404% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -633.432% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -43.925% |
| Notable Labs, Ltd. | 14.77 Million USD | -1584.509% |
| Liquidia Corporation | 87.98 Million USD | -182.781% |
| Mustang Bio, Inc. | 48.5 Million USD | -412.983% |
| Immunovant, Inc. | 282.7 Million USD | 11.994% |
| Quantum-Si incorporated | 111.65 Million USD | -122.823% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1003.628% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1069.897% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -143.895% |
| Acasti Pharma Inc. | 11.3 Million USD | -2101.593% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -985.471% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1457.021% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -434.575% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -21828.996% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1466.171% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -753.318% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -501.203% |
| PepGen Inc. | 84.76 Million USD | -193.516% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -739.668% |
| United Therapeutics Corporation | 885.1 Million USD | 71.89% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -986.614% |
| Solid Biosciences Inc. | 104.31 Million USD | -138.51% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -660.269% |
| Immuneering Corporation | 58.41 Million USD | -325.937% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4787.828% |
| Silo Pharma, Inc. | 3.92 Million USD | -6243.986% |
| Belite Bio, Inc | 31.66 Million USD | -685.657% |
| XOMA Corporation | 46.46 Million USD | -435.484% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -268.323% |
| Bionomics Limited | 17.89 Billion USD | 98.609% |
| Apogee Therapeutics, Inc. | 93 Million USD | -167.52% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 797.315% |
| uniQure N.V. | 285.08 Million USD | 12.727% |
| Cassava Sciences, Inc. | 105.95 Million USD | -134.814% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3303.539% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -28.112% |
| Forte Biosciences, Inc. | 32.47 Million USD | -666.087% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2894.456% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -746.409% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4373.247% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1650.894% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2698.988% |
| Altimmune, Inc. | 30.55 Million USD | -714.249% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 41.821% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 797.315% |
| Compugen Ltd. | 43.97 Million USD | -465.832% |
| Peak Bio, Inc. | 1249.13 USD | -19917922.944% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -235.675% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1011.616% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -2.308% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -771.674% |
| Zura Bio Limited | 62.63 Million USD | -297.206% |
| PolyPid Ltd. | 21.04 Million USD | -1082.238% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1428.643% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -771.674% |
| Instil Bio, Inc. | 85.78 Million USD | -190.03% |
| argenx SE | 1.53 Billion USD | 83.776% |
| Immunome, Inc. | 122.82 Million USD | -102.574% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -413.28% |
| Verona Pharma plc | 67.15 Million USD | -270.51% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -861.182% |
| Shattuck Labs, Inc. | 93.61 Million USD | -165.774% |
| CervoMed Inc. | 14.95 Million USD | -1563.363% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -251.897% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2812.008% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -387.847% |
| Moolec Science SA | 52.75 Million USD | -371.657% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1412.618% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -87.697% |
| AnaptysBio, Inc. | 181.56 Million USD | -37.03% |
| Design Therapeutics, Inc. | 78.19 Million USD | -218.202% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -185.845% |
| NeurAxis, Inc. | 8.82 Million USD | -2720.501% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1876.973% |
| Lumos Pharma, Inc. | 38.66 Million USD | -543.481% |
| Achilles Therapeutics plc | 75.25 Million USD | -230.612% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -861.182% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1746.055% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -838.789% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8382.894% |
| Nutriband Inc. | 5.73 Million USD | -4239.042% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -124.591% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -347.059% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -389.007% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -276.408% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -359.697% |
| Palisade Bio, Inc. | 13.32 Million USD | -1767.883% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -447.913% |
| Beam Therapeutics Inc. | 554.19 Million USD | 55.106% |
| Neurogene Inc. | 55.58 Million USD | -347.622% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -0.126% |
| AEON Biopharma, Inc. | 48.42 Million USD | -413.746% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -157.266% |
| Sesen Bio, Inc. | 78.38 Million USD | -217.426% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -197.863% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1876.675% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 44.832% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -183.083% |
| Athira Pharma, Inc. | 125.46 Million USD | -98.302% |
| Vaccinex, Inc. | 23.45 Million USD | -960.763% |
| HCW Biologics Inc. | 21.02 Million USD | -1083.221% |
| XOMA Corporation | 46.46 Million USD | -435.484% |
| Nektar Therapeutics | 190.9 Million USD | -30.329% |
| Arvinas, Inc. | 480 Million USD | 48.166% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10841.305% |
| Merus N.V. | 200.49 Million USD | -24.094% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -140.726% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -618.666% |
| Rezolute, Inc. | 70.38 Million USD | -253.477% |
| Clene Inc. | 41.07 Million USD | -505.756% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1419.079% |
| BeyondSpring Inc. | 24.86 Million USD | -900.611% |
| Synlogic, Inc. | 58.53 Million USD | -325.07% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1290.577% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -5438.78% |
| Peak Bio, Inc. | 1249.13 USD | -19917922.944% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -311.61% |
| Krystal Biotech, Inc. | 160.42 Million USD | -55.088% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 8.066% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 28.513% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -11436.054% |
| MannKind Corporation | 125.59 Million USD | -98.095% |
| Ikena Oncology, Inc. | 84.57 Million USD | -194.172% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2479.061% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -177.678% |
| Gossamer Bio, Inc. | 183.75 Million USD | -35.396% |
| CohBar, Inc. | 12.38 Million USD | -1908.363% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -390.502% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -802.045% |
| Legend Biotech Corporation | 583.14 Million USD | 57.334% |
| Mural Oncology plc | 192.07 Million USD | -29.536% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -270.533% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1441.021% |
| Disc Medicine, Inc. | 91.12 Million USD | -173.034% |
| Champions Oncology, Inc. | 28.11 Million USD | -785.101% |
| REGENXBIO Inc. | 321.15 Million USD | 22.529% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4540.76% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -346.234% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -538.598% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -117.566% |
| Vaxart, Inc. | 90.72 Million USD | -174.235% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2820.209% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -481.393% |
| Cellectis S.A. | 97.32 Million USD | -155.654% |
| Longeveron Inc. | 21.25 Million USD | -1070.833% |
| Repare Therapeutics Inc. | 167.35 Million USD | -48.665% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 81.717% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -228.907% |
| Revolution Medicines, Inc. | 498.76 Million USD | 50.116% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3640.259% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -466.051% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -233.559% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -257.294% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2149.566% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.789% |
| Denali Therapeutics Inc. | 527.23 Million USD | 52.81% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2774.109% |
| Veru Inc. | 101.34 Million USD | -145.492% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -962.938% |
| Cingulate Inc. | 22.75 Million USD | -993.194% |
| Passage Bio, Inc. | 108.38 Million USD | -129.545% |
| Context Therapeutics Inc. | 25.07 Million USD | -892.326% |
| Exicure, Inc. | 14.07 Million USD | -1667.562% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -20.74% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -474.587% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2611.062% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 1.458% |
| Nuvalent, Inc. | 149.49 Million USD | -66.432% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2984.232% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -140.041% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1059.97% |
| OmniAb, Inc. | 83.89 Million USD | -196.564% |
| Anew Medical, Inc. | 1.3 Million USD | -19026.242% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -659.376% |
| Lipocine Inc. | 15.08 Million USD | -1549.865% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -263.146% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -226.718% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -517.156% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -116.645% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1011.517% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 62.538% |
| Ocugen, Inc. | 71.56 Million USD | -247.649% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -165.061% |
| Q32 Bio Inc. | 92.68 Million USD | -168.453% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1075.035% |
| Alumis Inc. Common Stock | 158.17 Million USD | -57.296% |
| Equillium, Inc. | 50.6 Million USD | -391.645% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -298.683% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1689.227% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1218.847% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -429.918% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -129.382% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1907.645% |
| Dominari Holdings Inc. | 23.83 Million USD | -943.851% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2597.696% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1989.544% |
| Bio-Techne Corporation | 563.03 Million USD | 55.811% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 39.139% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 7.425% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -88.092% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1626.473% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -51.99% |
| Nkarta, Inc. | 131.65 Million USD | -88.987% |
| BioCardia, Inc. | 12.12 Million USD | -1952.652% |
| Iterum Therapeutics plc | 47.46 Million USD | -424.147% |